Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited covers the month of July 2020. The registrant is a foreign private issuer based in Melbourne, Australia, and files annual reports on Form 20-F. The filing incorporates by reference an Appendix 4C and a Quarterly Cash Flow Report dated July 30, 2020.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a "Quarterly Cash Flow Report" as an attachment but does not summarize the data within the body of this document.
Material Changes and Corporate Events
- NASDAQ Compliance: On July 15, 2020, the Company regained compliance with the NASDAQ minimum bid price requirement (Listing Rule 5550(a)(2)).
- Previous Deficiency: This compliance followed a February 5, 2020, notification that the Company's ADSs had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days, granting the Company a 180-day cure period.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the previously noted listing compliance issue, which has been resolved. No unusual items or contingencies are detailed in the text provided.
Investor Verification Checklist
- Verify the specific cash flow figures and financial position in the attached Appendix 4C and Quarterly Cash Flow Report, as they are not summarized in this text.
- Confirm the current trading price of ADSs to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for details on capital structure and outstanding securities.